New anti-body treatment defeats all mutations of Omicron
GlaxoSmithKline Plc said research shows its Covid19 antibody treatment is effective against the full combination of mutations in the new omicron variant.
The Brentford-based pharmaceutical company said it has seen an overall vaccine efficacy rate of 71% against all variants of Covid19 included in a study of over 24,000 adult subjects across six countries.
The preclinical data was generated through pseudo-virus testing of the combined known mutations of the Omicron variant, which included the maximum number of changes (37 mutations) identified to date in the spike protein, GSK said in a statement.
“From the outset of our collaboration with Vir we hypothesised that sotrovimab would have a high barrier to resistance and thus could deliver best-in-class potential for the early treatment of patients with Covid9,” said Dr Hal Barron, chief scientific officer at GSK.